F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in…
Data are based on analysis of the first 100 patients from an ongoing Phase 2b study of patients who have limited or no treatment options for invasive fungal infectionsOverall, a 44% response rate, defined as complete or partial response,…